Skip to main content
KWANGDONG PHARMACEUTICAL CO.,LTD logo

KWANGDONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 009290 ISIN · KR7009290008 KO Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2026-04-14 Major Shareholding Noti…
Country KR South Korea
Listing KO 009290

About KWANGDONG PHARMACEUTICAL CO.,LTD

https://eng.ekdp.com/

Kwangdong Pharmaceutical is a human healthcare company that develops, manufactures, and sells a diverse range of products, including pharmaceuticals and health-oriented beverages. Founded on the principle of the 'scientification of Oriental medicine,' the company integrates traditional Korean medicinal concepts with modern Western science. Its portfolio includes Over-the-Counter (OTC) and prescription (ETC) drugs, general health supplements, and traditional health foods. The company is also prominent in the consumer market with its popular beverage lines, featuring well-known products such as the Vita 500 vitamin drink and Corn Silk Tea. Additionally, Kwangdong is involved in the distribution of mineral water.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a Korean “주식등의 대량보유상황보고서” (Report on Large Holdings of Shares) under the Capital Markets Act, detailing the number of shares and ownership percentages of a major shareholder and related parties, including changes and contracts. This is a notification of significant share ownership levels crossing reporting thresholds, matching the Major Shareholding Notification category.
2026-04-14 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document presents detailed voting outcomes and resolutions from the company’s Regular Annual General Meeting (AGM) held on March 26, 2026, including approval of financial statements, dividend resolutions, director elections, and vote tallies. This aligns precisely with a Declaration of Voting Results for a shareholder meeting. Therefore, it is classified under ‘Declaration of Voting Results & Voting Rights Announcements (DVA).’
2026-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal filing titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” which reports the appointment, dismissal, or mid-term retirement of an outside (independent) director. It is submitted to the Financial Services Commission and the Korea Exchange and details board composition changes (outside director numbers before and after, term start and end dates, etc.). This matches the definition of a Board/Management Information filing (Code: MANG).
2026-03-26 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 1% confidence The document is a Korean "주요사항보고서" (Major Event Report) filed with the Financial Supervisory Service/Korea Exchange regarding the company’s decision to dispose of its own treasury shares due to stock option exercises. It details number of shares, disposal period, purpose, method (transferring treasury shares to option holders), and related shareholding changes. This falls squarely under a company’s transaction in its own shares (disposal/issuance of treasury stock). According to the classification definitions, this is a Transaction in Own Shares (POS).
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from Kwangdong Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit), and details regarding the external auditor. While it contains financial data, it is a formal regulatory announcement of the audit report's completion and submission to the regulator, rather than the full annual report itself. Given the document length and its nature as a formal notification of audit results, it fits the 'Audit Report / Information' (AR) category. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for Kwangdong Pharmaceutical Co., Ltd. for the 53rd fiscal year (2025). It contains comprehensive financial statements, management discussion and analysis, governance information, and detailed operational data. This is the standard Korean regulatory filing equivalent to a 10-K in the US market. It is not an announcement of a report, but the full report itself. FY 2025
2026-03-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.